Tesamorelin
A trans-3-hexenoyl-modified GHRH analogue FDA-approved for HIV-associated lipodystrophy.
How it works
Binds GHRH-R with strong potency, increasing GH and IGF-1. The lipodystrophy indication is driven by selective visceral-fat reduction.
Reported benefits
- 18% reduction in visceral adipose tissue at 26 weeks in HIV patients
- Improvement in lipid profile
- Possible benefit in NAFLD (off-label)
Dosage & administration
FDA label: 2 mg subcutaneously daily.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Tesamorelin for HIV-associated lipodystrophy
New England Journal of Medicine · 2007
Significant visceral fat reduction vs placebo over 26 weeks.
Safety & warnings
- Arthralgia, peripheral edema, hyperglycemia possible
- Discontinue if persistent injection-site reactions
- Avoid in malignancy
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
5 mg
TSM5
Box of 10 · $336
Single vial · $672
10 mg
TSM10
Box of 10 · $660
Single vial · $1,320
Related guides
BPC 157
A pentadecapeptide derived from human gastric juice with broad regenerative effects in pre-clinical models.
TB500 (Thymosin B4 Acetate)
A synthetic fragment of thymosin β-4 that promotes cell migration, angiogenesis, and tissue repair.
BPC + TB Blend
Combined BPC 157 and TB500 blend used in recovery protocols to overlap angiogenic and cytoskeletal effects.